Skip to main content
OpenTrials
Completed

NCT Number: NCT02648243

Impact of a Pharmacist-delivered Discharge and Follow-up Intervention for Patients With Acute Coronary Syndromes in Qatar

In Qatar, cardiovascular diseases (CVD) have become the leading cause of morbidity and mortality over the past two decades. Between 1991 and 2010, a total of 16,736 patients were admitted with ACS (Acute Coronary Syndrome) in Qatar. Despite the use of percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG), and pharmacological agents to acutely reduce vascular risk, ACS patients are at high risk of having further cardiovascular events. Consequently, secondary cardiovascular risk reduction therapy is needed for all CAD (Coronary Artery Disease) patients. Clinical practice guidelines recommend that following ACS, patients should receive indefinite treatment with aspirin, a beta blocker, an angiotensin converting enzyme inhibitor (ACEI) or alternatively angiotensin II receptor blocker (ARB) and a statin. Less than 80% of ACS patients in Qatar use this quadruple combination after discharge. This creates a significant opportunity for pharmacists to improve CVD management and outcomes in Qatar. Nothing is known about the impact of Qatar clinical pharmacists as direct patient-care team members at discharge and post-discharge on the short-term and long-term outcomes of ACS patients. The proposed study is aimed to determine this impact. The investigators hypothesize that a clinical pharmacist-delivered intervention consisting of medication reconciliation and counseling at discharge and tailored follow-up post-discharge will decrease hospital readmissions, emergency department (ED) visits and all-cause mortality at 3 month, 6 months and 12 months after hospital discharge when compared with control arm and pharmacist delivered intervention at discharge only among ACS patients. The investigators also hypothesize that the effect of the intervention will increase patients' adherence to evidence-based secondary prevention medications for CAD (Coronary Artery Disease), and patient satisfaction with pharmacy services. Besides, this intervention will reduce the treatment burden on patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Coronary Syndromes Acute Coronary Syndrome Cardiovascular Diseases Heart Diseases Myocardial Ischemia Stomatognathic Diseases Tooth Diseases Tooth, Impacted Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Dr. Maguy El Hajj

Doha, 2713, Qatar

About this study

Nothing is known about the impact of Qatar clinical pharmacists as direct patient-care team members at discharge and post-discharge on the short-term and long-term outcomes of patients with ACS at Heart Hospital in Qatar. This research project aims to determine this.

The investigators hypothesize that a clinical pharmacist-delivered intervention consisting of medication reconciliation and counseling at discharge and tailored follow-up post-discharge will decrease hospital readmissions, emergency department (ED) visits and all-cause mortality at 3 months, 6 months and 12 months after hospital discharge when compared with control arm and pharmacist delivered intervention at discharge only among ACS patients. The investigators also hypothesize that the effect of the intervention will increase patients' adherence to evidence-based secondary prevention medications for CAD, and patient satisfaction with pharmacy services. besides, this intervention will reduce the treatment burden on patients.

Study objectives:

  • To evaluate the effectiveness of clinical pharmacist-delivered intervention at discharge and tailored follow-up post-discharge on decreasing hospital readmissions, ED visits and mortality in ACS patients.
  • To evaluate the effectiveness of the intervention on improving patient adherence to evidence-based secondary prevention CAD medications.
  • To study the effect of the intervention on reducing the burden of treatment on patients.
  • To assess the effect of the intervention on increasing patient satisfaction with pharmacy services at Heart Hospital in Qatar.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least 18 years of age
  • Admitted to and discharged from any nonsurgical cardiology service at Heart Hospital with a diagnosis of ACS in the period from September 2015 to February 2016.

Exclusion criteria

  • Severe visual impairment
  • Severe hearing impairment
  • Inability to communicate in English or Arabic
  • Mental or psychiatric illness
  • Delirium or severe dementia
  • Cognitive impairment
  • Incomprehensible speech
  • Planned discharge to a location other than home (e.g. long-term care facility, nursing home, other medicine units etc.)
  • Plan for coronary artery bypass graft (CABG) surgery during hospitalization
  • Plan to leave Qatar in the next 12 months
  • A terminal illness with a high likelihood of death in the next 12 months.

Treatment and study plan

Structured intervention at discharge and tailored follow up post discharge

Behavioral

At discharge, pharmacist-delivered personalized intervention would include the following (30-60 minutes session): The pharmacist will perform medication reconciliation and will check the appropriateness and accuracy of discharge medications. - Other potential interventions that could be done by the pharmacist include in addition to medication initiation: dose and/or frequency optimization, changing ACEI with ARB if necessary, changing to another statin if needed, identification of inappropriate or duplicated therapy, etc.

The pharmacist will ensure that a follow-up plan for medication monitoring after discharge is communicated to the patient. The pharmacist will also provide a tailored and thorough counseling to the patient. In addition to the pharmacist delivered intervention at discharge (as described above), the study pharmacist will schedule 2 follow-up sessions (30-60 minutes each session) with the patients at 4 weeks of discharge and at 8 weeks of discharge.

Primary outcomes

  1. All-cause hospitalizations and cardiac-related hospital readmissions

    Time frame: 3 months post discharge

    This will be measured by the number (%) of hospital readmissions including hospitalizations for cardiac events, including coronary events, exacerbation of heart failure or arrhythmia. Coronary events will be defined as ACS, percutaneous coronary intervention, and/or coronary artery bypass graft. This outcome will be assessed by checking the Heart Hospital (HH) and Hamad Medical Corporation (HMC) medical records

  2. All-cause hospitalizations and cardiac-related hospital readmissions

    Time frame: 6 months post discharge

    This will be measured by the number (%) of hospital readmissions including hospitalizations for cardiac events, including coronary events, exacerbation of heart failure or arrhythmia. Coronary events will be defined as ACS, percutaneous coronary intervention, and/or coronary artery bypass graft. This outcome will be assessed by checking the Heart Hospital (HH) and Hamad Medical Corporation (HMC) medical records

  3. All-cause hospitalizations and cardiac-related hospital readmissions

    Time frame: 12 months post discharge

    This will be measured by the number (%) of hospital readmissions including hospitalizations for cardiac events, including coronary events, exacerbation of heart failure or arrhythmia. Coronary events will be defined as ACS, percutaneous coronary intervention, and/or coronary artery bypass graft. This outcome will be assessed by checking the Heart Hospital (HH) and Hamad Medical Corporation (HMC) medical records

Secondary outcomes

  1. All-cause mortality including cardiac-related mortality

    Time frame: 3 months, 6 months, and 12 months post discharge

    This outcome will be measured by the number (%) of deaths. It will be assessed by checking HH and HMC medical records during the designated follow-up periods. •

  2. ED visits including cardiac-related ED visits

    Time frame: 3 months, 6 months, and 12 months post discharge

    This outcome will be measured by the number (%) of ED visits. The outcome will be assessed by checking HH and HMC medical records

  3. Patient adherence to evidence-based secondary prevention medications for CAD

    Time frame: 3 months, 6 months, and 12 months post discharge

    Adherence will be measured from the refill records as well as by asking the patients to list the medications they are currently taking and by using the ARMS tool

  4. Burden of medications

    Time frame: 3 months, 6 months, and 12 months post discharge

    will be assessed using a questionnaire that will be adapted from a validated and translated questionnaire.

Sponsors and collaborators

Lead sponsor

Qatar University

Other

Collaborators

  • Hamad Medical Corporation
  • Weill Cornell Medical College in Qatar

Registry information

Official study title

Impact of a Pharmacist-delivered Discharge and Follow-up Intervention for Patients With Acute Coronary Syndromes in Qatar: a Randomized Controlled Trial

Important dates

Study start
2016
Primary completion
2019
Study completion
2019
First posted
Jan 7, 2016
Registry last updated
Mar 10, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.